Latest Clinical Ovarian Cancer Stories

2011-06-06 16:39:00

PITTSBURGH, June 6, 2011 /PRNewswire/ -- Dr. Bradley Monk of the Creighton University School of Medicine presented a new gynecologic cancer study at the 2011 American Society of Clinical Oncology (ASCO) Annual Symposium, June 5th in Chicago, Illinois. The study, titled, Acquired Drug Resistance in Gynecologic Cancer Detected by an In Vitro Assay, begins to answer the question of whether ChemoFx® Drug Response Marker test results taken in the primary setting can be...

2010-11-15 16:36:51

New research from the Centenary Institute finds a new death pathway that can break resistance Drug resistance is a major obstacle in curing ovarian cancer but new research from the Centenary Institute has discovered a treatment that kills ovarian cancer cells in a new way that can break the resistance mechanism. Published today in Autophagy, the researchers found the drug (FTY720) had a potent effect in human ovarian cancer cells, even in those resistant to cisplatin, the most commonly used...

2010-09-08 16:22:00

VANCOUVER, Sept. 8 /PRNewswire/ - Researchers with the Ovarian Cancer Research Program of BC (OvCaRe) reveal a major new cancer gene-ARID1A. Mutations are frequent in this gene and link two types of ovarian cancer to endometriosis. The research paper, ARID1A Mutations in Endometriosis-Associated Ovarian Carcinomas, published today in the New England Journal of Medicine. Researchers looked at over 600 samples of ovarian cancer, leading to the conclusion that the ARID1A mutation and loss of...

2010-07-13 09:56:00

FREDERICKSBURG, Va., July 13 /PRNewswire/ -- Fredericksburg Oncology is now accepting patients for a new clinical trial supported by the National Cancer Institute (NCI) to evaluate treatment for metastatic (advanced stage) melanoma. The current trial, designed at the Mayo Clinic, combines chemotherapy with targeted molecular agents in an effort to improve control of this difficult disease, reports Dr. Frederick C. Tucker, Jr., who heads this practice. "When discovered early, Melanoma is a...

2010-06-07 12:47:47

Newly reported results from a major clinical trial show that adding bevacizumab (Avastin) to standard frontline chemotherapy for women with advanced ovarian cancer and then continuing a maintenance dose of the drug afterwards significantly extends progression-free survival. Women receiving the new treatment regimen saw no worsening of their disease for 14.1 months, compared to 10.3 months for women receiving standard therapy. The international, multi-center, randomized, double-blind,...

2009-07-07 15:00:00

ANN ARBOR, Mich., July 7 /PRNewswire-USNewswire/ -- An analysis of almost 20,000 patient records from the Southwest Oncology Group's database of clinical trials finds, for the first time, that African-American breast, ovarian, and prostate cancer patients tend to die earlier than patients of other races even when they get identical medical treatment and other confounding socioeconomic factors are controlled for. The finding points to biological or host genetic factors as the potential source...

2009-05-02 14:20:00

Women who experience a second bout of uterine or ovarian cancer are in for some rare fortunate news.  New research reveals that treatment by combining chemotherapy drugs topotecan and docetaxel has proven effective in recurring episodes of these forms of cancer when treated by other drug combos during the initial occurrence, Reuters reported. This drug regimen has never been tested in patients with female reproductive cancers until this study.  A report published in the journal...

2009-03-16 09:00:00

New updates to the NCCN Clinical Practice Guidelines in Oncology(TM) for Ovarian Cancer were presented at the NCCN 14th Annual Conference on March 14. Notable additions to the NCCN Guidelines are a section on managing allergic reactions to chemotherapy agents and new agents for recurrence therapy. Robert J. Morgan, MD, of City of Hope Comprehensive Cancer Center presented the updated NCCN Guidelines that continue to stress early detection of ovarian cancer and the enrollment of patients...

2008-06-27 12:02:13

By Jason Gertzen, The Kansas City Star, Mo. Jun. 27--Local ovarian cancer patients soon will begin receiving new treatments, signaling advances both in the fight against the disease and in the region's bioscience aspirations. The University of Kansas Cancer Center on Thursday announced the official start of work to test a new ovarian cancer drug. The Phase 1 clinical trial marks the first time that a drug developed by KU scientists is remaining here for this development phase. In...

Latest Clinical Ovarian Cancer Reference Libraries

Clinical Leukemia
2012-05-18 15:34:28

Clinical Leukemia is a peer-reviewed medical journal published by CIG Media Group. The journal publishes articles on detection, diagnosis, prevention, and treatment of leukemia. The main emphasis is on recent scientific developments in all areas related to leukemia. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance, gene and antisense therapy; pathology, markers, and prognostic indicators, chemoprevention strategies,...

Clinical Ovarian Cancer
2012-05-18 14:46:55

Clinical Ovarian Cancer is a peer-reviewed medical journal published by CIG Media Group. It is devoted to articles on detection, diagnosis, prevention, and treatment of ovarian cancer. The main emphasis is on recent scientific developments in all areas pertaining to ovarian cancer. Specific areas or interest include clinical research, drug sensitivity and resistance, gene therapy, pathology, markers, prognostic indicators, chemoprevention strategies, multimodality therapy; and integration...

More Articles (2 articles) »
Word of the Day
  • A cloth or covering, more or less ornamented, laid over the saddle or furniture of a horse, especially of a sumpter-horse or horse of state.
  • Clothing, especially sumptuous clothing; equipment; outfit.
  • To cover with a caparison, as a horse.
  • To dress sumptuously; adorn with rich dress.
This word ultimately comes from the Medieval Latin 'cappa,' cloak.